Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 196 to 210 of 1834 results for carers

  1. Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]

    In development Reference number: GID-TA11519 Expected publication date:  12 June 2026

  2. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST22)

    Evidence-based recommendations on ataluren (Translarna) for Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk.

  3. Suicide prevention (QS189)

    This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.

  4. Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]

    In development Reference number: GID-TA11386 Expected publication date: TBC

  5. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

  6. Mental health of adults in contact with the criminal justice system (NG66)

    This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.

  7. Stage 1: referral points

    Referral points to virtual wards are similar to traditional models of care. Our guidance and advice can help you decide where to provide care and what to consider.

  8. Anticipatory prescribing:- What is the clinical and cost effectiveness of anticipatory prescribing for patients dying in their usual place of residence, on patient and carer reported symptoms at end of life?

    prescribing for patients dying in their usual place of residence, on patient and carer reported symptoms at end of life? Any explanatory...

  9. Crohn's disease: management (NG129)

    This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.

  10. Research is needed on the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).

    institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life). Any explanatory...

  11. Teprotumumab for treating thyroid eye disease [ID6432]

    In development Reference number: GID-TA11531 Expected publication date: TBC

  12. Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]

    In development Reference number: GID-TA11561 Expected publication date:  11 March 2026

  13. Major trauma: service delivery (NG40)

    This guideline covers the organisation and provision of major trauma services in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by providing a systematic approach to the delivery of major trauma care. It does not cover services for people with burns.

  14. Standard principles of infection prevention and control:- What are the barriers to compliance with the standard principles of infection prevention and control that patients and carers experience in their own homes?

    standard principles of infection prevention and control that patients and carers experience in their own homes? Any explanatory notes(if...

  15. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026